NCT06563999 2024-12-10
NUMER
Sun Yat-sen University
Phase 2 Recruiting
Clinical Trials
4 trialsNCT05341583 2024-08-23
Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT05241028 2023-10-10
Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT05498064 2022-08-11
A Real World Study of Ensartinib in Advanced ALK-positive NSCLC
Peking Union Medical College Hospital
Recruiting